Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01602315
Registration number
NCT01602315
Ethics application status
Date submitted
16/05/2012
Date registered
18/05/2012
Date last updated
29/12/2020
Titles & IDs
Public title
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Query!
Scientific title
A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open-label Study of BYL719 in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Query!
Secondary ID [1]
0
0
2011-006017-34
Query!
Secondary ID [2]
0
0
CBYL719X2104
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Recurrent Head and Neck Squamous Cell Carcinoma
0
0
Query!
Metastatic Head and Neck Squamous Cell Carcinoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Cancer
0
0
0
0
Query!
Head and neck
Query!
Other
0
0
0
0
Query!
Research that is not of generic health relevance and not applicable to specific health categories listed above
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - BYL719 as film-coated (FC) whole tablets
Treatment: Drugs - BYL719 as dispersible tablets (DT)
Other interventions - cetuximab
Treatment: Drugs - BYL719 drink suspension
Experimental: Phase Ib: A-BYL719 FC whole tab+cetux - Oral film-coated tablets without swallowing dysfunction.
Experimental: Phase II: 2-Cetuximab - Cetuximab in patients naive to cetuximab (phase ll)
Experimental: Phase Ib: B-BYL719 FC drink sus+cetux - Crushed film-coated (FC) tablets as an oral suspension with swallowing dysfunction.
Experimental: Phase II: 3-BYL719 + Cetuximab - BYL719 + cetuximab in patients resistant to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
Experimental: Phase II: 1-BYL719 + Cetuximab - BYL719 + Cetuximab in Patients naive to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
Experimental: Phase Ib: C-BYL719 DT+cetux - Dispersible tablet with swallowing dysfunction administered via a gastrostomy tube (G-tube)
Experimental: Phase II: Cross over - patients received BYL719 at RP2D in combination with cetuximab.
Treatment: Drugs: BYL719 as film-coated (FC) whole tablets
Oral alpha-specific PI3K inhibitor
Treatment: Drugs: BYL719 as dispersible tablets (DT)
New formulation of the oral alpha-specific PI3K inhibitor
Other interventions: cetuximab
Recombinant chimeric monoclonal antibody driven against EGFR
Treatment: Drugs: BYL719 drink suspension
Oral alpha-specific PI3K inhibitor
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Phase Ib Arms A: Probability That Dose Limiting Toxicities (DLTs) Rate is in the Recommended Phase 2 Dose in Cycle 1 (Cycle 1=28 Days)
Query!
Assessment method [1]
0
0
Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm A (BYL719 administered as a whole tablet in patients able to swallow the tablets). Dose recommendation was based on posterior summaries including the mean, median, standard deviation, 95%-credibility interval, and the probability that the true DLT rate for each dose combination lies in one of the following categories: (0%, 16%) under-dosing; (16%, 35%) targeted toxicity; (35%, 100%) excessive toxicity. The combination treatment was considered superior to cetuximab alone if the posterior probability (HR > 1) < 10%, and the posterior median HR < 0.7.
Query!
Timepoint [1]
0
0
until disease progression or intolerable toxicity (approximately 6 months)
Query!
Primary outcome [2]
0
0
Phase Ib Arm B: Probability That Distribution of Dose Limiting Toxicities (DLTs) is in the Recommended Phase 2 Dose in Cycle 1 (Cycle 1=28 Days)
Query!
Assessment method [2]
0
0
Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm B (crushed film-coated tablets as an oral suspension with swallowing dysfunction). Dose recommendation was based on posterior summaries including the mean, median, standard deviation, 95%-credibility interval, and the probability that the true DLT rate for each dose combination lies in one of the following categories: (0%, 16%) under-dosing; (16%, 35%) targeted toxicity; (35%, 100%) excessive toxicity. The combination treatment was considered superior to cetuximab alone if the posterior probability (HR > 1) < 10%, and the posterior median HR < 0.7.
Query!
Timepoint [2]
0
0
until disease progression or intolerable toxicity (approximately 6 months)
Query!
Primary outcome [3]
0
0
For Phase Ib: Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1 (28 Days)
Query!
Assessment method [3]
0
0
Estimation of Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm A (BYL719 administered as a whole tablet in patients able to swallow the tablets) and arm B (BYL719 administered as a drinkable suspension in patients with swallowing dysfunction).
6 months is an approximate timeframe.
Query!
Timepoint [3]
0
0
until disease progression or intolerable toxicity (approximately 6 months)
Query!
Primary outcome [4]
0
0
Phase II Arms 1 and 2: Progression Free Survival (PFS) as Per RECIST v1.1 by Central Radiology Review
Query!
Assessment method [4]
0
0
Assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab.
6 months is an approximate timeframe.
Query!
Timepoint [4]
0
0
approximately 6 months
Query!
Primary outcome [5]
0
0
Phase II Arm 3: Progression Free Survival (PFS) as Per RECIST V1.1
Query!
Assessment method [5]
0
0
Assessment of the anti-tumor activity of BYL719 in combination with cetuximab in patients resistant to platinum-based therapy and cetuximab.
Query!
Timepoint [5]
0
0
approximately 6 months
Query!
Primary outcome [6]
0
0
Phase Ib: Area Under Curve (AUC) 0-24 for BYL719 by Treatment
Query!
Assessment method [6]
0
0
Comparison of single-dose exposure of BYL719 dispersible tablet via G-tube in combination with cetuximab in RM HNSCC to that of Arm A (film-coated tables)
Query!
Timepoint [6]
0
0
6 months
Query!
Secondary outcome [1]
0
0
Phase II: Progression Free Survival (PFS) as Per RECIST v 1.1
Query!
Assessment method [1]
0
0
Phase II, Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab
Query!
Timepoint [1]
0
0
approximately 6 months
Query!
Secondary outcome [2]
0
0
Phase Ib: Progression Free Survival (PFS) as Per RECIST v1.1
Query!
Assessment method [2]
0
0
Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm A, B and C.
Query!
Timepoint [2]
0
0
approximately 6 months
Query!
Secondary outcome [3]
0
0
Phase II: Randomized Best Overall Response as Per RECIST v1.1
Query!
Assessment method [3]
0
0
Scheme 1 (Arms 1 and 2): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
Query!
Timepoint [3]
0
0
approximately 6 months
Query!
Secondary outcome [4]
0
0
Phase II: Non-Randomized Best Overall Response as Per RECIST v1.1
Query!
Assessment method [4]
0
0
Scheme 1 (Arm 3): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
Query!
Timepoint [4]
0
0
approximately 6 months
Query!
Secondary outcome [5]
0
0
Phase II: Randomized Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1
Query!
Assessment method [5]
0
0
Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arms 1 and 2.
Query!
Timepoint [5]
0
0
approximately 6 months
Query!
Secondary outcome [6]
0
0
Phase II: Non-Randomized Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1
Query!
Assessment method [6]
0
0
Scheme 1 (arm 3): Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm 3 (non-randomized arm)
Query!
Timepoint [6]
0
0
approximately 6 months
Query!
Secondary outcome [7]
0
0
Phase II: Randomized Overall Survival (OS) by Treatment
Query!
Assessment method [7]
0
0
Scheme 1 (Arms 1 and 2): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
Query!
Timepoint [7]
0
0
approximately 1 year
Query!
Secondary outcome [8]
0
0
Phase II: Non-Randomized Overall Survival (OS) by Treatment
Query!
Assessment method [8]
0
0
Scheme 1 (Arm 3): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
Query!
Timepoint [8]
0
0
approximately 1 year
Query!
Secondary outcome [9]
0
0
For Phase Ib: Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1
Query!
Assessment method [9]
0
0
Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm A, B and C
CR=complete response PR=partial response
Query!
Timepoint [9]
0
0
approximately 6 months
Query!
Secondary outcome [10]
0
0
Phase II, Scheme 1 (Arm 2B): Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1
Query!
Assessment method [10]
0
0
Phase II: Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab.
Complete response (CR); Partial response (PR); Stable disease (SD)
Query!
Timepoint [10]
0
0
Approximately 6 months
Query!
Secondary outcome [11]
0
0
Phase II, Scheme 2 (Arm 2B): Overall Survival (OS) for the Cross-over
Query!
Assessment method [11]
0
0
Phase II, Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab.
Query!
Timepoint [11]
0
0
approximately 1 year
Query!
Secondary outcome [12]
0
0
Phase Ib: Primary Plasma Pharmacokinetic Parameters for BYL719 by Treatment
Query!
Assessment method [12]
0
0
Non compartmental PK parameters derived after single dose at Cycle 1 Day 1
Query!
Timepoint [12]
0
0
1 to 24 hours post dose (Day 1 Cycle 1)
Query!
Secondary outcome [13]
0
0
Phase Ib: Cmax for BYL719 by Treatment
Query!
Assessment method [13]
0
0
Non compartmental Cmax derived after single dose at Cycle 1 Day 1
Query!
Timepoint [13]
0
0
Day 1 Cycle 1
Query!
Secondary outcome [14]
0
0
Phase Ib: Tmax for BYL719 by Treatment
Query!
Assessment method [14]
0
0
Non compartmental Cmax derived after single dose at Cycle 1 Day 1
Query!
Timepoint [14]
0
0
Day 1 Cycle 1
Query!
Secondary outcome [15]
0
0
Phase Ib: Plasma Pharmacokinetic Parameters for BYL719 After Continuous Dose Administration (Steady State)
Query!
Assessment method [15]
0
0
Non compartmental PK parameters derived after single dose at Cycle 1 Day 1
Query!
Timepoint [15]
0
0
Day 1 Cycle 1
Query!
Secondary outcome [16]
0
0
Phase Ib: Cmax for BYL719 After Continuous Dose Administration (Steady State)
Query!
Assessment method [16]
0
0
Non compartmental PK parameters derived after single dose at Cycle 1 Day 1
Query!
Timepoint [16]
0
0
Day 1 Cycle 1
Query!
Secondary outcome [17]
0
0
Phase Ib: Tmax for BYL719 After Continuous Dose Administration (Steady State)
Query!
Assessment method [17]
0
0
Non compartmental PK parameters derived after single dose at Cycle 1 Day 1
Query!
Timepoint [17]
0
0
Day 1 Cycle 1
Query!
Secondary outcome [18]
0
0
Phase Ib: Notable Abnormal Vital Signs by Treatment
Query!
Assessment method [18]
0
0
Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm A, B and C.
Query!
Timepoint [18]
0
0
approximately 6 months
Query!
Secondary outcome [19]
0
0
Phase Ib: Number of Patients With Notable Electrocardiogram (ECG) Abnormalities
Query!
Assessment method [19]
0
0
Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm A, B and C.
Query!
Timepoint [19]
0
0
baseline, post baseline
Query!
Secondary outcome [20]
0
0
For Phase II: Notable Abnormal Vital Signs by Treatment
Query!
Assessment method [20]
0
0
Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm 1, 2 and 2B.
Query!
Timepoint [20]
0
0
approximately 6 months
Query!
Secondary outcome [21]
0
0
For Phase II: Number of Patients With Notable Electrocardiogram (ECG) Abnormalities
Query!
Assessment method [21]
0
0
Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm 1, 2 and 2B.
Query!
Timepoint [21]
0
0
baseline, post baseline during the entire study period (approximately 1 year)
Query!
Secondary outcome [22]
0
0
Phase II: Progression Free Survival (PFS) Based on Investigator's Assessment With Treatment
Query!
Assessment method [22]
0
0
Assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
Query!
Timepoint [22]
0
0
approximately 6 months
Query!
Eligibility
Key inclusion criteria
- Age = 18 years
- Patients with histologically/cytologically-confirmed HNSCC
- Patients must be resistant to platinum-based chemotherapy, or be ineligible (due to
medical comorbidities) or intolerant to platinum-based therapy per medical history
- For Phase Ib, there is no restriction on the number of prior therapies for recurrent
or metastatic disease
- For Phase II, patients may have received a maximum of 1 prior line of therapy for
recurrent or metastatic disease
- For Phase Ib, prior cetuximab or other EGFR-targeted antibody therapy is allowed
regardless of the prior treatment settings.
- For Phase II, Arms 1 and 2, prior cetuximab or other EGFR-targeted antibody therapy is
allowed only if administered in the induction setting, or concurrently with radiation
in the curative setting, with the last dose of cetuximab administered at least 12
months prior to starting the study treatment. For Arm 3, prior cetuximab must have
been administered in the curative, recurrent or metastatic disease setting and disease
progression documented within 9 months of the last dose of cetuximab administered in
that setting. This regimen (including both platinum and cetuximab) must be the most
recent anti-neoplastic treatment regimen administered.
- Patients with swallowing dysfunction who are unable to swallow BYL719 whole tablets
and are not using feeding tubes for study drug administration can participate in the
Phase Ib Arm B. For the Phase II, these patients with swallowing dysfunction may
participate if able to drink the suspension and results of Arm B confirm the use of
this method. Patients with swallowing dysfunction requiring G tube (G/PEG tube) for
study drug administration may participate in Phase II if Arm C confirms dispersible
tablet via G tube administration is permitted if the administration of drinkable
suspension of BYL719 is allowed to be used in Phase II.
- Availability of a representative tumor specimen. Patients enrolled in Arm 3 of Phase
II must have disease sites amenable to biopsy unless prior agreement between Novartis
and the Investigator.
- At least one measurable or non-measurable lesion as per RECIST 1.1 criteria for
patients in Phase Ib; Measurable disease as determined by RECIST v1.1 for Phase II
patients
- World Health Organization (WHO) Performance Status (PS) = 2
- Adequate organ function
- Negative serum pregnancy test.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Prior treatment with PI3K-inhibitors
- Patients with a prior serious infusion reaction to cetuximab
- Patients with uncontrolled CNS tumor metastatic involvement
- Clinically significant cardiac disease or impaired cardiac function
- Patients with diabetes mellitus
- Impaired GI function or GI disease
- History of another malignancy within 2 years prior to starting study treatment
- Pregnant or nursing (lactating) women
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1/Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/11/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
16/09/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
179
Query!
Recruitment in Australia
Recruitment state(s)
VIC,WA
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Melbourne
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
3000 - Melbourne
Query!
Recruitment postcode(s) [2]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
South Carolina
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Tennessee
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Ontario
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Lyon Cedex
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Toulouse Cedex 9
Query!
Country [15]
0
0
Hong Kong
Query!
State/province [15]
0
0
Shatin, New Territories
Query!
Country [16]
0
0
Korea, Republic of
Query!
State/province [16]
0
0
Korea
Query!
Country [17]
0
0
Korea, Republic of
Query!
State/province [17]
0
0
Seoul
Query!
Country [18]
0
0
Netherlands
Query!
State/province [18]
0
0
Maastricht
Query!
Country [19]
0
0
Netherlands
Query!
State/province [19]
0
0
Nijmegen
Query!
Country [20]
0
0
Singapore
Query!
State/province [20]
0
0
Singapore
Query!
Country [21]
0
0
Taiwan
Query!
State/province [21]
0
0
Taiwan ROC
Query!
Country [22]
0
0
Taiwan
Query!
State/province [22]
0
0
Taoyuan/ Taiwan ROC
Query!
Country [23]
0
0
Taiwan
Query!
State/province [23]
0
0
Taipei
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was a multi-center, open-label, Phase Ib dose escalation /Phase II study in recurrent or
metastatic head and neck squamous cell carcinoma (RM HNSCC) patients considered to be
resistant, ineligible or intolerant to platinum-based chemotherapy. The Phase Ib included
three arms. Three different methods of administration and two different BYL719 formulations
were studied to determine the MTD and/or RP2D of BYL719 in combination with cetuximab:
Arm A - film-coated whole tablets were orally administered to patients who were able to
swallow the tablets; Arm B - a drinkable suspension prepared from crushed film-coated tablets
was administered orally to patients with swallowing dysfunction Arm C - a suspension from a
dispersible tablet administered via G-tube, in patients with swallowing dysfunction. Arm C
was used to investigate the pharmacokinetics (PK), compared to Arm A (film coated tablet),
and safety of the dispersible tablet of the dispersible tablet formulation of BYL719.
The Phase II investigated the clinical efficacy of BYL719 and consisted of an open label,
randomized Phase II part investigating BYL719 in combination with cetuximab compared to
cetuximab alone in patients resistant or intolerant to platinum and naïve to cetuximab
(Scheme 1: Arm 1 and Arm 2), and a non-randomized Phase II part Scheme 2: Arm 3. In addition,
patients who experienced disease progression in Arm 2 (cetuximab) were allowed to switch to
the combination regimen (cross-over, Arm 2B). The safety of the BYL719 in combination with
cetuximab was also further characterized in Arms 1, 2B and 3.
Patients were treated until progression of disease), unacceptable toxicity, or withdrawal of
informed consent, whichever occurred first (except for phase II Arm 2 had the opportunity to
crossover to the combination treatment (Arm 2B). In the follow-up period all patients had to
complete the safety follow-up assessments within 30 days after the last dose of the study
treatment. Patients who did not have disease progression at the time of discontinuation of
study treatment were radiologically followed for disease status until disease progression,
initiation of subsequent anticancer therapies, or death, whichever occurred first. In
addition, all patients enrolled in Phase II were followed for survival.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01602315
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01602315
Download to PDF